SOURCE: Intelomed, Inc.

InteloMed, Inc.

October 25, 2016 09:30 ET

InteloMed, Inc. to Exhibit Non-Invasive Monitoring System for Assessing Dialysis Tolerance at the National Renal Administrators Association (NRAA) Annual Fall Conference

The InteloMed CVInsight® Patient Monitoring & Informatics System will be demonstrated on site

PITTSBURGH, PA--(Marketwired - Oct 25, 2016) - InteloMed, Inc., an emerging leader and developer of advanced non-invasive systems for intelligent patient monitoring, will be exhibiting the CVInsight® Patient Monitoring & Informatics System for continuous monitoring of cardiovascular stress to assess dialysis treatment tolerance at the National Renal Administrators Association (NRAA) Annual Fall Conference. This year's event is being held on October 26 - 29 in San Diego, CA. The NRAA Annual Fall Conference brings together the dialysis and kidney community for a multidisciplinary discussion on the clinical and delivery aspects of patient care and advocacy.

"InteloMed supports NRAA's goal to provide life-sustaining dialysis care to end stage renal disease patients, and this annual conference provides a unique opportunity to demonstrate advancements in the field," said InteloMed CEO Jill Schiaparelli. "We look forward to sharing the clinical benefits of the CVInsight System with the dialysis community."

Demonstrations of the CVInsight Monitoring System will be available at the InteloMed booth, number TT06. For more information about the event, visit http://www.nraa.org/index.php/meetings/meetings/annual-fall-conference-a-workshop

About InteloMed

InteloMed is redefining the standard of care in patient monitoring and informatics through its intelligent, multi-dimensional, non-invasive CVInsight® Patient Monitoring & Informatics System.

Providing an unprecedented level of physiologic insight, the CVInsight® Monitoring System is an easy-to-use, multi-parameter system for monitoring cardiovascular stress. It empowers clinicians with non-invasive, real-time, dynamic, and actionable information about a patient's dialysis tolerance. Based on patented and proprietary algorithms, the system provides clinician set alerts to notify healthcare providers of changes in the patient's tolerance to dialysis treatment, allowing them to intervene to avoid dialysis interruptions that can have serious patient consequences.

The CVInsight® Patient Monitoring and Informatics System is FDA-cleared and CE-marked and has launched commercially in the United States.

InteloMed is headquartered in Wexford, PA.

For more information, visit us at www.InteloMed.com.

About NRAA

NRAA is a voluntary organization representing dialysis providers throughout the United States. Our membership is primarily community-based small dialysis organizations (SDOs) and medium-sized dialysis organizations (MDOs), both for-profit and non-profit providers serving patients in urban, rural and suburban areas in both free-standing and hospital-based facilities. For more information, go to www.nraa.org.

Safe Harbor Statement

Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage qualified employees, the acceptance of new products by doctors and hospitals, changes in the regulatory environment and healthcare legislation, the need to keep pace with technological changes, our dependence on third party manufacturers to produce components of our technology platform on time and to our specifications, and the successful implementation of our commercial strategies.

Contact Information